Denali sells FDA voucher for $195M to support neurodegenerative pipeline

BioSpace

Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.

pharminent June 19, 2026 (Last updated: June 22, 2026)

BioSpace

Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.

Related Stories